Company Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products.
It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction.
It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system.
BioCardia, Inc. is based in Sunnyvale, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Peter Altman |
Contact Details
Address: 320 Soquel Way Sunnyvale, California 94085 United States | |
| Phone | 650 226 0120 |
| Website | biocardia.com |
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U507 |
| ISIN Number | US09060U6064 |
| Employer ID | 23-2753988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter A. Altman Ph.D. | Chief Executive Officer, President and Director |
| David McClung | Chief Financial Officer |
| Edward M. Gillis | Senior Vice President of Devices |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2025 | 8-K | Current Report |
| Nov 24, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 3, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 30, 2025 | 8-K | Current Report |
| Oct 29, 2025 | 10-Q/A | [Amend] Quarterly report |
| Oct 24, 2025 | 424B5 | Filing |
| Oct 7, 2025 | 8-K | Current Report |